natgillin/translations-raw huggingface dataset:
The method of claim 28, wherein during said saturation step said synthetic substance is introduced in said cavity through said first holes and/or through said second holes. 
šupljinu (1) kroz spomenute prve rupe (5) i/ili kroz spomenute druge rupe (7) prilikom spomenutog koraka saturiranja. .
The dosage form of any one of claims 1-3, wherein the core is in the form of a tablet, wherein the content of rasagiline is 1.0 mg. The dosage form of claim 6, comprising 45.0 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, 3.5 mg of hypromellose, 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, 1.9 mg of talc extra fine, and 2.0 mg of a color coating agent. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 1,0 mg, a tableta sadrži 45,0 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
the third stream compressed in the compressor is cooled in a heat exchanger (21) by exchanging heat with the first stream, without employing a reliquefaction apparatus using a separate refrigerant, the third stream cooled in the heat exchanger is decompressed by decompressing means (22,52), and 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se treću struju, ukapljenu u izmjenjivaču topline (21), dekomprimira elementom za dekomprimiranje (22).
The aqueous formulation of claim 4 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 2, naznačena time što sadrži 0,1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
a thermo-sealable plastic coating (42) is coated on at least one of the inner surface of the shell (14) and the outer surface of the cup body (22); 
Izolirani spremnik u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, što staza za kontakte (3) potpuno okružuje tijelo čaše (22) 1 ljusku (14).
the shell 14 is then removed from the mandrel and seated inside the corresponding shaped receiving member 20, see Figure 10; 
- > ljuska 14 se tada ukloni s ove jezgre i stavi u odgovarajuće oblikovani element za prihvaćanje 20, vidi sliku 10;
This macrocapsule is preferably positioned entirely within the insulator jacket 86. 
Ova makrokapsula 52 je poželjno postavljena potpuno unutar izolacijskog plašta 86.
Other suitable pharmaceutical agents, in addition to anti-obesity agents, that can be used in combination with the compounds of the present invention include agents useful in the treatment of metabolic related disorders and/or concomitant diseases thereof. 
Pripravak u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačen time, da se koristi u postupku liječenja metabolički-posredovanih poremećaja ljudskog ili životinjskog tijela terapijom.
The composition of claim 1, wherein the excipient, diluent or carrier is a pharmaceutically acceptable excipient, diluent or carrier. 
Pripravak naznačen time da sadrži jedan ili više bakterijskih sojeva mliječne kiseline prema zahtjevu 1 i farmaceutski prihvatljiv ekscipijent, nosač ili sredstvo za otapanje.
Data transmission device 1 operates as follows. 
Naprava za prijenos podataka 1 radi kako slijedi.
The method of claim 1, wherein the plurality of liposomes comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 4, naznačen time, što liposom sadrži jednolamelarne vezikule, višelamelarne vezikule, ili njihovu mješavinu.
The sealing material does not necessary have to be resilient, but can also be inelastic, as it is used once only. 
Nije nužno da materijal za brtvljenje bude elastičan, već on može biti i neelastičan, budući da se koristi samo jednom.
the human Vk3-20 gene segment is present in a rearrangement with a human Jk1 gene segment. 
humani genski segment Vk-20 prisutan je u preuređivanju s humanim genskim segmentom Jk.
is selected from the group consisting of H, OH, OCH3, and OCH2CH3; is selected from the group consisting of H, OH, OCH3, and OCH2CH3; 
R2 je odabran iz grupe koja se sastoji od H, OH, OCHr; i OCH2CHz;; nje 31li 4; ako je RI OH, onda R2 nije OH;
a first heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen with at least 80% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: 1, 3, 5, 32, 34 or 36; and 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da sekvenca proteina NDV-F ima najmanje 90% identiteta sekvence prema sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54.
wherein R1, R2 and R6 are as defined in claim 9 . 
(Vb) pri čemu su R2 i R6 kao što su definirani u zahtjevu 3.
is selected from hydrogen and alkyl. 
Ri, je izabran od vodika i alkila.
wherein the wild-type leukocidin subunit comprises the amino acid sequence SEQ ID NO: 17 and wherein the mutant staphylococcal leukocidin subunit polypeptide comprises an amino acid substitution at a position corresponding to K102 of SEQ ID NO: 17, 
ili izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 16, 17, 21, 22, 23, 24, 25 ili 26, pri čemu mutant stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K102 u SEQ ID NO: 17, što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina.
A molecule or composition according to claim 7 for use in the prevention or treatment of clinical Alzheimer's disease. 
Molekula u skladu s patentnim zahtjevom 4, naznačena time što je namijenjena upotrebi u liječenju ili sprječavanju Alzheimerove bolesti, gdje je navedena Alzheimerova bolest klinički stadij Alzheimerove bolesti.
The patent application U.S. Pat. 
Datum objave europske prijave patenta:
or a mixture of R and S isomers thereof, or an (E) or (Z) isomer of any one of the above compounds. 
ili (Z) izomer bilo kojeg od gore navedenih spojeva.
There are dextromethorphan combination products with ephedrine and acetaminophen on the market, used as bronchodilators and are indicated for the treatment of cold with cough symptoms. 
Na tržištu se nalaze kombinirani proizvodi dekstrometorfana s efedrinom i acetaminofenom, koji se upotrebljavaju kao bronhodilatori i daju se za liječenje prehlade sa simptomima kašlja.
A method as claimed in claim 1 wherein the profile index is derived from one or more link indexes relating to feature(s) of the link that influence the behaviour of a driver of a vehicle travelling along that link. 
Postupak prema zahtjevu 1, naznačen time da je indeksirani profil deriviran od jedne ili više indeksirane poveznice (22) koje se odnose na svojstva poveznice koja utječe na ponašanje vozača vozila koje se kreće duž poveznice.
In further embodiments, the Core is selected from the group consisting of: and 
L je polialkilen glikolni linker; i Jezgra se bira iz skupine koju čine: j
The transmitter of claim 9, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Predajnik iz patentnog zahtjeva 9, pri čemu informacija signaliziranja L1 ima ID informaciju podatkovnog reza koja identificira podatkovni rez.
The system of claim 1 wherein the drive means are further configured to provide a drive signal having the first frequency applied continuously and the second frequency pulsed in response to the sensed vacuum in the aspiration line. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time, da je sustav namješten tako da se primarni pokretački signal primjenjuje neprekidno i daje impuls sekundarnom pokretačkom signalu.
The integrity monitoring system as claimed in any one of the preceding claims, wherein the vibration sensor (2, 12, 22, 22a, 22b, 32a, 32b, 32c, 42a, 42b, 42c, 52, 62) is an acoustic sensor such as a microphone, a hydrophone, a seismometer and/or an optical fibre acoustic sensor. 
Sustav za nadziranje integriteta u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je vibracijski senzor (2, 12, 22, 22a, 22b, 324, 32b, 320, 42a, 42b, 42c, 52, 62) akustički senzor kao što je mikrofon, hidrofon, seizmometar i/ili akustički senzor optičkog vlakna.
The solution was cooled to room temperature, filtered and the filtered solid washed with ethyl acetate. 
Otopina je ohlađena na sobnu temperaturu, filtrirana i krutina nakon filtriranja je isprana etil acetatom.
Membrane fraction in GnRH binding buffer (130 ul containing 25 ug protein for human and macaque receptors or 12 ug for rat receptors) are added to wells together with 20 ul of competing ligand at varying concentrations. 
Membranska frakcija u puferu za vezanje GnRH (130 ul koji sadrži 25 ug proteina za ljudske 1 makakovske receptore ili 12 ug za štakorske receptore) dodane su u jažice zajedno s 20 ul kompeticijskog liganda, u različitim koncentracijama.
The present invention includes in its definition any racemic, optically-active, enantiomerically pure, mixture of diastereoisomers, stereoisomeric form of the compound of Formula I, or mixtures thereof, which possesses the above-mentioned activity. 
Ovaj izum u svojoj definiciji uključuje bilo koji recemični, optički aktivan, enentiomerski čist, stereoizomerni spoj ili smjesu dijastereoizomera spoja prikazanog Formulom I, ili njihove smjese koje posjeduju gore navedenu aktivnost.
A compound according to claim 6 in which R1 represents a pyrazole or thiazole rings optionally substituted with one or two halogen atoms, methyl or trifluoromethyl groups and R4 represents a group SR7 or OR7, where R7 represents a linear or branched C1-C8 alkyl group optionally substituted by fluorine atoms. 
Spoj u sklađu sa zahtjevom 6 u kojem R' predstavlja pirazolski ili tiazolski prsten opcionalno supstituirane s jednim ili dva halogena atoma, metilne ili trifluorometilne skupine, i R* predstavlja SR" ili OR" skupinu, gdje R' predstavlja linearnu ili razgranatu Ci-Cg alkilnu skupinu opcionalno supstituiranu atomima fluora.
the following abbreviations have been used:- 
koji postupak sadrži slijedeće korake:
The oligomeric compound according to any one of claims 1 or 2, wherein the nucleic acid target is selected from the group consisting of a microRNA, a mRNA, a IncRNA (long non-coding RNA), a snRNA, snoRNA, and a viral RNA. 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da je ciljna nuklemska kiselina odabrana iz skupine koja se sastoji od mikroRNK, mRNK, IncRNK (duge nekodirajuće RNK), snRNK, snoRNK te virusne RNK.
The composition or vaccine of claim 2, wherein the polynucleotide encoding the NDV-F polypeptide, the operably linked SV40 promoter and SV40 polyA signal are inserted in the intergenic site 1 (IG1) locus of HVT genome. 
NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:5, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma.
a step d2) for eliminating halogenated compounds by passing said first portion through at least one suitable guard bed, 
* korak d2) uklanjanja halogeniranih spojeva prolaskom navedenog prvog dijela kroz barem jedan pogodan zaštitni sloj,
The compound or a pharmaceutically acceptable acid addition salt thereof according to [2], wherein R is a methyl group, an ethyl group, a fluoromethyl group or a difluoromethyl group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 2, naznačen time što R je metilna skupina, etilna skupina, fluorometilna skupina ili difluorometilna skupina.
capable of binding an FcY receptor with comparable or greater affinity than a wild-type IgG1 Fc-domain. 
sposobna vezati se za FcY receptor s usporedivim ili većim afinitetom nego za Fc domenu IgG1 divljeg tipa.
In this way, if it is necessary to apply modifications to the communication module 19 it is not necessary to rewrite the program 18 but it is sufficient to recompile the module 19 . 
Na taj način, ako je potrebno unijeti modifikacije u komunikacijski modul 19, nije potrebno ponovno upisivati program 18, već je dovoljno rekompilirati modul 19.
the target cells are selected from the group consisting of lung, ovarian, brain, breast, prostate and skin cancer cells; or 
regulatorna RNK je izabrana iz grupe koja se sastoji od negativnih jednolančanih RNA, ribozima i RNK-mamaca;
The method according to claim 18, wherein the insulinotropic peptide has the amino acid sequence (SEQ. 
Postupak u skladu sa zahtjevom 18, naznačen time, da inzulinotropni peptid ima amino kiselinsku sekvencu (SEQ.
A packaging according to claim 1, wherein the first and second sides comprise indentations along a perimeter for receiving corresponding protrusions provided on said first and second outer parts so as to provide the attachment between said sides and said outer parts. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time, što prve i druge strane sadržavaju nazubljenja duž oboda radi prihvaćanja odgovarajućih izbočenja koja se nalaze na navedenim prvim i drugim vanjskim dijelovima, tako da osiguraju pričvršćenje između navedenih strana i navedenih vanjskih dijelova.
Method of certification of digitally signed electronic mail which is carried out by means of a telecommunications operator, the method comprising: 
Postupak potvrđivanja digitalno potpisane elektronske pošte, kojeg provodi telekomunikacijski operator, naznačen time što se postupak sastoji u:
Mill according to claim 12, wherein the at least one hatch for each grinding chamber is automatically controlled via sensor and is dependent on temperature of rotating mass of the rubbish. 
Mlin (20) sukladno zahtjevu 12 ili 13, pri čemu je otvor (42) automatski kontroliran ovisno o temperaturi rotirajuće mase otpada R.
The thoracic and abdominal aortas are removed intact, opened longitudinally along the ventral surface, and fixed in neutral-buffered formalin after excision of samples from standard sites in the thoracic and abdominal aorta for histological examination and lipid composition and synthesis studies. 
Torakalna i abdominalna aorta su uklonjene intaktne, otvorene longitudinalno uzduž ventralne površine i fiksirane u neutralno-puferiran formalin nakon ekscizije uzoraka sa standardnih mjesta torakalne i abdominalne aorte za histološke preglede i proučen je sastav lipida i sinteza.
derived from a DA strain or an ACI strain; 
(a) izvedena je od DA soja ili ACI soja;
Although it is believed that no polymerisation initiator is strictly needed, it is believed that the polymerizable resin base advantageously comprises a polymerisation initiator, e.g. 
Mada se vjeruje da je inicijator polimerizacije striktno potreban, vjeruje se da je pogodno da smola koja polimerizira sadrži inicijator polimerizacije, npr.
Compounds of the formula I as claimed in claims 1 to 8 in which 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 8, gdje
Surprisingly, the inventors discovered that the metallic lead was recovered from processes of the inventive concept in the form of a micro- or nanoporous mixed matrix in which the lead formed micro- or nanometer sized structures (typically needles/wires) that trapped some of the electroprocessing/electrodeposition solvent and a substantial quantity of molecular hydrogen (i.e., H2). Most notably, such a matrix had a black appearance and a remarkably low bulk density. Indeed, in most of the experimental test runs the matrix was observed to float on the solvent and had a density of less than 1 g/cm3. 
Olovna supstanca koja sadrži kruti oblik olova s čistoćom od najmanje 98%, molekularnim vodikom, i ionom olova obogaćeno elektroprocesorsko otapalo koje je vodeno otapalo koje sadrži alkan sulfonsku kiselinu, kelator, i ima pH manji od 7, pri čemu kruti oblik olova, vodik, i elektroprocesorsko otapalo tvori mikroporoznu ili nanoporoznu miješanu matricu gustoće manje od 5 g/em', pri čemu je pH obogaćenog elektroprocesorskog otapala HR P20190579 T1 manji od 7. Supstancu olova sukladno patentnom zahtjevu 12 pri čemu je miješana matrica gustoće manje od 3 g/em', ili pri čemu je miješana matrica gustoće manje od 1 g/cm'.
In another embodiment, the batch is acceptable for inclusion in the pharmaceutical composition only if its percentage of brominated tyrosine so measured is less than 0.1%. 
Postupak prema patentnom zahtjevu 9, naznačen time, da je šarža prihvatljiva za uključivanje u farmaceutski sastav samo onda, kada je njen postotak tako izmjerenog bromiranog tirozina manji od 0,1%.
is selected from the group consisting of —S—, —O—, and —NR2—; 
X? je odabran iz skupine koja se sastoji od -S-, i -NR"-;
The holding system according to claim 2, wherein the bar-shaped ground support body comprises an external thread at least in a lower partial area, said external thread being aligned with and extending through a central hole in the disk-shaped base surface, the central hole having an internal thread. 
Sustav nosača (1) prema zahtjevu 5, naznačen time da tijelo potpornih stupova (22) u obliku šipke u barem jednom donjem dijelu obuhvaća vanjski navoj (24), koji je usklađen s jednom središnjom rupom s unutrašnjim navojem, koji je namješten u središtu tanjuraste plohe za potporu na strani podloge (28).
A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient. 
Farmaceutski sastav prema patentnom zahtjevu 2 koji sadrži spoj formule IIB ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje R13 je -(CH2)0-3CR17R18NR20R21 ili -(CH2)0-3CR17R18NR17C(O)NR20R21.
A counter as claimed in claim 8 wherein said first engagement means is deflected radially outwardly after a predetermined degree of rotation of said first ring member, said predetermined amount of rotation of said first ring member being less than a full rotation of said first ring member about said common axis. 
Brojač kao što je zahtijevano u patentnom zahtjevu 1, gdje su navedena prva sredstva za angažiranje (704) skrenuta radijalno prema vani poslije predodređenog stupnja rotacije navedenog prvog prstenastog člana (201), pri čemu navedeni prethodno određeni broj rotacija navedenog prvog prstenastog člana je manji od pune rotacije navedenog prvog prstenastog člana oko navedene zajedničke osi.
The formulation according to claim 1, wherein said formulation comprises at least one pharmaceutically acceptable excipient selected from the group comprising fillers, solvents, pH adjusting agents, sweeteners, aromatic agents and preservatives. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačeno time da navedeni sastav sadrži bar jedan farmaceutski prihvatljiv ekscipijent izabran među grupom koja obuhvaća punila, otapala, sredstva za reguliranje kiselosti, zaslađivače, aromatična sredstva i konzervanse.
Typical water contents of the lozenges are 5-20 wt. %, especially 10-15 wt. %. 
Tipična količina vode u tableti je 5-20 mas.%, posebno 10-15 mas.%.
The system according to claim 1, wherein the liquid supply inlet further comprises a liquid supply manifold for removably receiving a liquid supply container. 
Sustav prema zahtjevu 1, naznačen time da ulazni otvor za dovod tekućine nadalje sadrži razvodnik za napajanje tekućinom (24) za odstranjivo prihvaćanje spremnika za napajanje tekućinom (20).
3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione as intermediate in the preparation of the compound of formula (I) according to claim 8. 
-[2-fluor-4-(trifluormetil)fenil]-1H-pirol-2,5-dion [image], naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 8.
% Staphylococcus is the amount of Staphylococcus bacteria expressed as percentage of the total amount of bacteria; and wherein Y represents the chance of success. 
%Staphylococcus je količina Staphylococcus bakterija izražena kao postotak ukupne količine bakterija; i pri čemu Y predstavlja vjerojatnost uspjeha.
The beverage production process takes place during the closed state of the extraction module shown in Fig. 4. 
Postupak proizvodnje napitka se događa za vrijeme zatvorenog položaja modula za ekstrakciju koji je prikazan na slici 4.
The modified nucleobase can be a 5-methylcytosine. 
Oligomer prema zahtjevu 2, naznačen time da je modificirana nukleobaza 5-metilcitozin.
the second polypeptide comprises a variable heavy chain (VH) domain comprising a VH-HVR1, a VH-HVR2, and a VH-VHR3; 
(b) drugi polipeptid obuhvaća domenu varijabilnog lakog lanca (VL) koja se sastoji od VL-HVRI1, VL-HVR2 te VH-HVR3;
The solid pharmaceutical composition of clause 1, which is substantially free of lubricant. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja ne sadrži lubrikant.
It lies within the scope of the invention for the diaper accessory to contain a predefined set of movement patterns and/or excretion patterns. 
Postupak prema jednom od zahtjeva 1 do 3, kod kojeg modul pelene (2) obuhvaća unaprijed definirani skup uzoraka pokreta i/ili uzoraka izlučevina.
The antenna or hybrid antenna of any one of claims 1 - 5, wherein the at least one electromagnetic signal is a radio signal; and/or wherein an AC/DC conductivity of the conductive composite layer ranges from about 0.1 to about 10,000 S/cm. 
Antena ili hibridna antena prema bilo kojem od zahtjeva 1 - 5, pri čemu je najmanje jedan elektromagnetni signal radio signal; i/ili pri čemu se provodljivost naizmjenične struje/jednosmjerne struje provodnog kompozitnog sloja nalazi u opsegu od oko 0,1 do oko 10.000 S/em.
Composition according to claim 6 wherein the donepezil hydrochloride is donepezil hydrochloride of polymorphic form I or IV. 
Pripravak prema patentnom zahtjevu 4, takav da donepezil hidroklorid je donepezil hidroklorid polimorfnog oblika ili IV.
A compound of Formula I: or a pharmaceutically acceptable salt, ester or prodrug thereof, for use in a method of treating acute opioid toxicity or overdose for a period of over one hour comprising a single administration of the compound to a subject in need thereof, wherein; 
za uporabu u postupku liječenja akutne opioidne toksičnosti ili predoziranja tijemom razdoblja od preko jednog sata sadrži jednokratnu primjenu navedenog spoja subjektu kojem je nužno. Spoj za uporabu sukladno patentnom zahtjevu 16, pri čemu je navedeni subjekt opioidno iskusan pacijent koji nije ovisnik.
A compound of formula (I): wherein represents -NHCONR4R5 or -NHCSNR4R5 or -NH-heterocyclyl wherein heterocyclyl represents thiadiazolyl or oxadiazolyl, and wherein the heterocyclyl group is optionally substituted by one or more (e.g. 
predstavlja -NHCONR4R5ili-NHCSNR4R5ili-NH-heterociklil, pri čemu heterociklil predstavlja tiadiazolil ili oksadiazolil, i pri čemu je heterociklil grupa po izboru supstituirana s jednom ili više (npr.
The use of ascorbic acid or of a physiologically acceptable salt thereof for the preparation of a formulation for the prevention and treatment of fungal infections. The use according to claim 1, wherein said fungal infection is a recurrence. 
Upotreba askorbinske kiseline ili njene farmaceutski prihvatljive soli za proizvodnju pripravka za topikalnu primjenu za prevenciju i liječenje vaginalnih gljivičnih infekcija, pri čemu se spomenuti pripravak primjenjuje nakon završetka standardnog liječenja protiv bakterijskih, gljivičnih ili protozojskih infekcija.
the code concavities of said longitudinal code pattern being formed so that at least one of the tips of said neighbouring key code contacting portions will only contact a corresponding code concavity of said longitudinal code pattern of the key blade upon fully inserting said key into said key slot. 
- > barem jedno od drugih kodnih udubljenja u navedenom kodnom uzorku oblikovano je tako da, nakon potpunog umetanja ključa u navedenu odgovarajuću cilindar bravu, ne dolazi u kontakt sa odgovarajućom izbočenom stopicom na čepiću za zaključavanje.